查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363982

全球EB病毒诊断与治疗市场2023-2030

Global Epstein-Barr Virus Diagnosis and Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 198 Pages | 商品交期: 2-3个工作天内

价格

预计全球 Epstein-Barr 病毒诊断和治疗市场在预测期内（2023-2030 年）将以 5.1% 的复合年增长率成长。 EB 病毒 (EBV) 的广泛流行是创造其治疗需求的关键因素，进而推动全球 EBV 诊断和治疗市场的发展。 EBV 是一种疱疹病毒，感染后通常作为有机体存在于咽喉上皮组织和淋巴细胞中。大多数人都携带该病毒，血液检查通常会显示低水平的 EBV 抗体。此外，多发性硬化症 (MS) 是一种无法治癒的自体免疫疾病，全世界有 280 万人深受其苦。根据美国多发性硬化症协会的数据，被诊断出患有多发性硬化症的人的中枢神经系统会受到渐进性损害，并且可能会损失约七年的预期寿命。哈佛大学陈曾熙公共卫生学院的研究人员确定，感染该疾病的最大风险因素可能是先前感染过爱泼斯坦-巴尔病毒（EBV）。

细分市场前景

全球EB病毒诊断和治疗市场按诊断和治疗进行细分。根据诊断，市场分为基于实验室的测试和 POC 测试。根据治疗方法，市场细分为抗病毒药物（阿昔洛韦、更昔洛韦、地昔洛韦）和其他药物（抗发炎药、退烧药等）。在诊断中，护理点子细分市场预计将占据相当大的市场份额。护理点测试工具在可在非诊断环境中诊断的适应症方面开闢了广泛的选择。实验室。

抗病毒药物子细分市场预计将在全球 Epstein-Barr 病毒诊断和治疗市场中占据相当大的份额

其中，抗病毒检测细分市场预计将在全球EB病毒诊断和治疗市场中占据相当大的份额。抗病毒药物是治疗传染病时最常用的药物，也是主要传染病之一。传染性单核细胞增多症，也称为“单核细胞增多症”，是一种传染病。 EBV 是传染性单核球增多症最常见的原因，但其他病毒也可能引起这种疾病。它在青少年和年轻人中很常见，尤其是大学生。感染 EBV 的青少年和年轻人中至少有四分之一会出现传染性单核细胞增多症。已知可引起传染性单核细胞增多症或单核细胞增多症的 EBV 感染史以及某些类型的癌症被认为是多发性硬化症 (MS) 最强的危险因子。

区域展望

全球EB病毒诊断和治疗市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，北美预计将在全球市场中占据显着份额。自体免疫疾病病例的增加以及由此导致的抗体检测需求的增加，以及政府为提高公众对健康保险计划优势的认识而采取的倡议，是预计推动区域市场增长的一些关键因素。

亚太地区预计全球EB病毒诊断和治疗市场将以显着的复合年增长率成长

在所有地区中，亚太地区预计在预测期内将以可观的复合年增长率成长。区域增长归因于一般人口数量的增加以及由于该地区新疾病病例增加而导致的临床试验数量的增加。 2022 年 5 月，美国国立卫生研究院 (NIH) 旗下的国家过敏和传染病研究所 (NIAID) 启动了一项早期临床试验，以评估 Epstein-Barr 病毒 (EBV) 的研究性预防疫苗。 EBV 是传染性单核球增多症（「单核球增多症」）的主要原因，并与某些癌症和自体免疫疾病有关。第一阶段研究是十多年来仅有的两项测试研究性 EBV 疫苗的研究之一。它将在马里兰州贝塞斯达的 NIH 临床中心进行。

因此，该国在采用 Epstein-Barr 病毒诊断和治疗市场解决方案方面发生了重大转变。据印度医学研究委员会称，中国于2020年4月向印度发送了50万份快速抗体检测试剂盒（ICMR）。此外，中国研发公司更专注于开发生物特异性抗体测试，而大多数外国公司主要关注抗CD3抗体。由于创新生物特异性抗体的发现和一系列预期的产品发布活动，中国抗体检测市场正在不断扩大。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Viracta Therapeutics, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Atara Biotherapeutics, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • AlloVir, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按诊断分類的全球 Epstein-Barr 病毒诊断和治疗市场
    • 基于实验室的测试
    • 概念验证测试
  • 按治疗分類的全球 Epstein-Barr 病毒诊断和治疗市场
    • 抗病毒药物（阿昔洛韦、更昔洛韦、地昔洛韦）
    • 其他药物（抗发炎、解热等）

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Advenchen Laboratories LLC
  • Arno Therapeutics Inc.
  • bluebird bio Inc.
  • Cell Medica Ltd.
  • Epiphany Biosciences Inc.
  • Genocea Biosciences Inc.
  • Omeros Corp.
  • TC BioPharm Ltd.
  • Theravectys SA
  • Viracta Therapeutics Inc.
  • Vironika LLC
  • ViroStatics srl
Product Code: OMR2027688

Title: Global Epstein - Barr Virus Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Treatment (Lab-Based Test and POC test), by Diagnosis (Antiviral Drugs, and Other Drugs),Forecast Period (2023-2030).

The global Epstein - Barr virus diagnosis and treatment market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period (2023-2030). The considerable prevalence of the Epstein-Barr virus (EBV) is a key factor creating demand for its treatment which in turn driving the global EBV diagnosis and treatment market. The EBV is a herpes virus that normally resides after infection as an organism in the epithelial tissues of the throat and lymphocytes. Most humans carry the virus and blood tests will often show low levels of EBV antibodies. Moreover, Multiple sclerosis (MS) is an incurable autoimmune disease that afflicts 2.8 million people worldwide. People diagnosed with MS experience progressive damage to their central nervous system and can lose about seven years of their life expectancy, according to the National Multiple Sclerosis Society. Researchers at the Harvard T.H. Chan School of Public Health determined that the biggest risk factor for contracting the disease may be previous infection with the Epstein-Barr virus (EBV).

Segmental Outlook

The global Epstein - Barr virus diagnosis and treatment market is segmented on the diagnosis, and treatment. Based on the diagnosis, the market is sub-segmented into lab-based test and POC test. Based on the treatment, the market is sub-segmented into antiviral drugs (Acyclovir, ganciclovir, desciclovir), and other drugs (Anti-inflammatory, Antipyretic and other). Among the diagnosis, the Point of care sub-segment is anticipated to hold a considerable share of the market Point-of-care testing tools have opened up a wide range of options in terms of the indications that can be diagnosed in settings other than a laboratory.

The Antiviral drug Sub-Segment is Anticipated to Hold a Considerable Share of the Global Epstein - Barr virus diagnosis and Treatment Market

Among the treatment, the antiviral test sub-segment is expected to hold a considerable share of the global Epstein - Barr virus diagnosis and Treatment market. Antiviral drugs are the most common drug given in case of infectious diseases and one the major infectious disease The infectious mononucleosis, also called "mono," is a contagious disease. EBV is the most common cause of infectious mononucleosis, but other viruses can also cause this disease. It is common among teenagers and young adults, especially college students. At least one out of four teenagers and young adults who get infected with EBV will develop infectious mononucleosis. A history of infection with EBV known for causing infectious mononucleosis, or mono, and certain types of cancer is believed to be the strongest risk factor for multiple sclerosis (MS).

Regional Outlook

The global Epstein - Barr virus diagnosis and treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe. The increasing autoimmune disease cases and the resulting increase in demand for antibody tests, as well as government initiatives to raise public awareness of the advantages of health insurance programs, are some of the key factors anticipated to propel the regional market growth.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Epstein - Barr virus diagnosis and Treatment Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to rise number of generic population and increase in number of clinical trials owing to rise in cases of new diseases in the region. In May 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has launched an early-stage clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV). EBV is the primary cause of infectious mononucleosis ("mono") and is associated with certain cancers and autoimmune diseases. The Phase 1 study is one of only two studies to test an investigational EBV vaccine in more than a decade. It will be conducted at the NIH Clinical Center in Bethesda, Maryland.

Hence, there is considerable shift of the country towards the adoption of the Epstein - Barr virus diagnosis and Treatment market solutions. According to the Indian Council of Medical Research, China sent 500,000 rapid antibody testing kits to India in April 2020. (ICMR). Additionally, Chinese R&D firms are concentrating more on developing bio-specific antibody tests whereas the majority of foreign firms are primarily concerned with anti-CD3 antibodies. The Chinese antibody testing market is expanding due to the discovery of innovative bio-specific antibodies and a number of anticipated product launch events.

Market Players Outlook

The major companies serving the Epstein - Barr virus diagnosis and treatment market include Advenchen Laboratories LLC, Arno Therapeutics Inc, bluebird bio Inc, Cell Medica Ltd, Epiphany Biosciences Inc, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in March 2023, ModeX Therapeutics and Merck announced the collaboration, which is expected to advance the development of ModeX's MDX-2201, an investigational vaccine targeting the Epstein-Barr virus (EBV). Under the agreement, the two companies will work together to continue the preclinical development of MDX-2201. They also will collaborate to file an investigational new drug (IND) application with the US Food and Drug Administration requesting clearance to test the vaccine candidate for EBV in clinical trials.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Epstein - Barr virus diagnosis and Treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Viracta Therapeutics, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Atara Biotherapeutics, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. AlloVir, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Epstein-Barr Virus diagnosis and Treatment Market by Diagnosis
    • 4.1.1. Lab based test
    • 4.1.2. POC Test
  • 4.2. Global Epstein-Barr Virus diagnosis and Treatment Market by Treatment
    • 4.2.1. Antiviral drugs (Acyclovir, ganciclovir, desciclovir)
    • 4.2.2. Other Drugs (Anti-inflammatory, Antipyretic and other)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Advenchen Laboratories LLC
  • 6.2. Arno Therapeutics Inc.
  • 6.3. bluebird bio Inc.
  • 6.4. Cell Medica Ltd.
  • 6.5. Epiphany Biosciences Inc.
  • 6.6. Genocea Biosciences Inc.
  • 6.7. Omeros Corp.
  • 6.8. TC BioPharm Ltd.
  • 6.9. Theravectys SA
  • 6.10. Viracta Therapeutics Inc.
  • 6.11. Vironika LLC
  • 6.12. ViroStatics srl

LIST OF TABLES

  • 1. GLOBAL EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 2. GLOBAL LAB BASED TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL POC TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 5. GLOBAL ANTIVIRAL DRUGS FOR EPSTEIN-BARR VIRUS TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 6. GLOBAL OTHER DRUGS FOR EPSTEIN-BARR VIRUS TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. NORTH AMERICAN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 9. NORTH AMERICAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 10. NORTH AMERICAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 11. EUROPEAN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 12. EUROPEAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 13. EUROPEAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 14. ASIA- PACIFIC EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 15. ASIA- PACIFIC EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 16. ASIA- PACIFIC EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 17. REST OF THE WORLD EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18. REST OF THE WORLD EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 19. REST OF THE WORLD EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL EPSTEIN-BARR VIRUS MARKET SHARE BY DIAGNOSIS, 2022 VS 2030 (%)
  • 2. GLOBAL LAB BASED TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS MARKETSHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL POC TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKETSHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL EPSTEIN-BARR VIRUS MARKETSHARE BY TREATMENT, 2022 VS 2030 (%)
  • 5. GLOBAL ANTIVIRAL DRUGS FOR EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL OTHER DRUGS EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKETSHARE BY REGION, 2022 VS 2030 (%)
  • 8. US EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 9. CANADA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 10. UK EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 11. FRANCE EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. GERMANY EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. ITALY EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. SPAIN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. REST OF EUROPE EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. INDIA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CHINA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. JAPAN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. SOUTH KOREA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. REST OF ASIA-PACIFIC EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. REST OF THE WORLD EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)